We partner with marketing and communications leadership at four families of health & nutrition companies: B2B ingredient suppliers, consumer brands, clinics, food groups in transition. The problem is structural, not functional.
You'll recognise them. The vocabulary changes from segment to segment — the dynamic doesn't.
Your R&D or clinical team produces solid expertise. Marketing simplifies it, the press distorts it, social channels flatten it into wellness clichés. The final message holds up to neither ChatGPT, nor journalists, nor university nutritionists.
In a market saturated with "natural," "clean label," "science-based" and "sustainable," your product page, brochure and sales keynote could be swapped with a competitor's. Your differentiation evaporates into the category's semantic fog.
Each function has its own version of the story. Buyers, consumers, prescribers and journalists detect the inconsistency before you fix it. In health and nutrition, inconsistency is a direct loss of trust.
What doesn't change: the responsibility to bring a credible voice to the surface in a noisy category. We work across these four configurations with a shared method and segment-calibrated deliverables.
You sell to formulators, R&D leads, industrial buyers. Your buyers read the papers before meeting you. Your sales team gets stuck on €/kg comparisons when your cost-in-use or clinical dossier should be winning.
You sell to consumers in a market saturated with influencers, dubious claims and wellness lifestyle. You have to simplify without over-promising, educate without boring, differentiate without trading on fear.
You lead communications at a clinic, practice or medical institution. You have to build a brand that's medically credible, commercially desirable, and falls into neither the cold-clinical nor the Instagram-wellness trap.
You manage communications at a group or BU mid-transition: UPF, Nutri-Score, NOVA, pesticide and sustainability scrutiny. You're looking for a partner who holds under media pressure and arms your posture before the crisis.
We don't sell retainers "in principle." Every engagement produces tangible, sourced, reusable assets that survive past our intervention. No single-use slides.
Translate scientific substance into a tenable commercial narrative — once, for every function: R&D, marketing, sales, press, leadership.
Build or sharpen a health brand that doesn't look like a generic pharma lab — and doesn't look like a wellness influencer.
Articles, white papers, ebooks, controlled simplification, CEO and expert thought leadership, themed series per audience.
From calibrated press kit to placement in health, nutrition and consumer newsrooms. Pitch by pitch, no spray-and-pray.
Arm your teams without betraying the science or promising what EFSA, FDA or ANSES don't allow. Claim-safe by design.
Pre-written defence line on sensitive subjects (UPF, NOVA, Nutri-Score, pesticides, health claims), before the crisis breaks.
Make your brand exist when ChatGPT, Perplexity and Gemini answer a question in your category — B2B and B2C alike.
Each phase produces deliverables, not slides. The framework doesn't change by segment: the substance does.
Understand before acting. Audit of your audiences, category, scientific estate and current discourse.
From concept to creation. Message house, long-form editorial production, audience-specific variations, scientific and legal validation.
Make your message resonate. Multi-channel distribution: press, LinkedIn, paid campaigns, events, GEO.
Measure to improve. LLM citability monitoring, share of voice, press pickup, sales conversion. Iterate every quarter.
Best for: foundational narrative construction, continuous editorial production, reputational monitoring, GEO management. Your marketing team keeps the wheel; we carry the voice.
Rebrand, flagship white paper, ad-hoc press dispositif, CEO keynote, team training, reputational crisis. Dense intervention, closed perimeter, dated deliverables.
No — four client families: B2B ingredient suppliers and biotechs, consumer health & nutrition brands, clinics, and food groups in transition. But the core of the work is B2B ingredients: RCTs, EFSA dossiers and conference posters turned into commercial pipeline.
Precisely. A scientific dossier wins R&D committees, not RFPs. We translate the evidence into per-target arguments (formulator, buyer, quality), battle cards, and content that AI answer engines can cite.
Everything is tailored: the scope calibrates to your brief. After a 30-minute conversation and a read of your material, you receive a free quote within 5 days — no commitment.
Quarterly review on KPIs defined in month one: qualified leads, press pickups, visibility across five AIs. A monthly review is noise; a yearly review is an alibi.
Good: I don't replace it, I reinforce it. I work in your tools and routines, on what is most often missing in-house: turning the science into messages that R&D, legal and sales sign off. Depending on the need, that's a targeted mission, team training or ad interim support.
The world’s second-largest nutraceuticals market, worth USD 17 billion, with 51 per cent of Q3 sales made online: ‘Made in the EU’ is opening the door to the Chinese market. The label alone is not enough to win over consumers.
In brief — The FDA wants to make GRAS notifications, currently voluntary, mandatory. A fragile legal basis since the Loper Bright ruling (2024): what ingredient suppliers targeting the United States are risking.
In brief — Substituting 20% of a chickpea-teff base with carob flour raises fibre by 51%, cuts starch digestibility by 28% and lifts post-cooking firmness from 3.08 N to 4.83 N (Frontiers in Nutrition, 2026).
